{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:58Z","timestamp":1792225438760,"version":"4.4.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011234","name":"Bio-Rad Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH-RO1CA 184798-04"],"award-info":[{"award-number":["NIH-RO1CA 184798-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that accounts for 15\u201320% of all cases of leukemia. CML is caused by a translocation between chromosomes 9 and 22 which creates an abnormal fusion gene, <jats:italic>BCR<\/jats:italic>::<jats:italic>ABL1<\/jats:italic>. The amount of <jats:italic>BCR<\/jats:italic>::<jats:italic>ABL1<\/jats:italic> transcript RNA is a marker of disease progression and the effectiveness of tyrosine kinase inhibitor (TKI) treatment. This study determined the analytical and clinical performance of a droplet digital PCR based assay (QXDx BCR-ABL %IS Kit; Bio-Rad) for <jats:italic>BCR<\/jats:italic>::<jats:italic>ABL1<\/jats:italic> quantification. The test has a limit of detection of MR4.7 (0.002%) and a linear range of MR0.3\u20134.7 (50\u20130.002%IS). Reproducibility of results across multiple sites, days, instruments, and users was evaluated using panels made from <jats:italic>BCR<\/jats:italic>::<jats:italic>ABL1<\/jats:italic> positive patient samples. Clinical performance of the assay was evaluated on patient samples and compared to an existing FDA-cleared test. The reproducibility study noted negligible contributions to variance from site, instrument, day, and user for samples spanning from MR 0.7\u20134.2. The assay demonstrated excellent clinical correlation with the comparator test using a Deming regression with a Pearson R of 0.99, slope of 1.037 and intercept of 0.1084. This data establishes that the QXDx<jats:sup>\u2122<\/jats:sup> BCR-ABL %IS Kit is an accurate, precise, and sensitive system for the diagnosis and monitoring of CML.<\/jats:p>","DOI":"10.1371\/journal.pone.0265278","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:39:33Z","timestamp":1647538773000},"page":"e0265278","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia"],"prefix":"10.1371","volume":"17","author":[{"given":"Dawne N.","family":"Shelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4442-7220","authenticated-orcid":true,"given":"Prasanthi","family":"Bhagavatula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hauenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"9","key":"pone.0265278.ref001","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"JP Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"pone.0265278.ref002","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"A Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"pone.0265278.ref003","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"M Baccarani","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"pone.0265278.ref004","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"D Verma","year":"2009","journal-title":"Blood"},{"issue":"4","key":"pone.0265278.ref005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","article-title":"Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations","volume":"9","author":"T Zhang","year":"2007","journal-title":"J Mol Diagn"},{"issue":"8","key":"pone.0265278.ref006","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"S Branford","year":"2008","journal-title":"Blood"},{"key":"pone.0265278.ref007","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the proposed recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and for expressing results on an international scale","volume":"20","author":"S Branford","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"pone.0265278.ref008","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1586\/14737159.2013.835573","article-title":"BCR-ABL1 PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring","volume":"13","author":"MH Luu","year":"2013","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"pone.0265278.ref009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"T Hughes","year":"2006","journal-title":"Blood"},{"issue":"5","key":"pone.0265278.ref010","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"NC Cross","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"pone.0265278.ref011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"TP Hughes","year":"2016","journal-title":"Blood"},{"issue":"3","key":"pone.0265278.ref012","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjh.16506","article-title":"Prospects for achieving treatment-free remission in chronic myeloid leukaemia","volume":"190","author":"G Saglio","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0265278.ref013","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicenter, non-randomised, trial","volume":"19","author":"S Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0265278.ref014","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1097\/HS9.0000000000000496","article-title":"Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice","volume":"4","author":"CCB Kockerols","year":"2020","journal-title":"Hemasphere"},{"issue":"13","key":"pone.0265278.ref015","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1080\/10428194.2019.1622103","article-title":"Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia","volume":"60","author":"M Dragani","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"pone.0265278.ref016","doi-asserted-by":"crossref","first-page":"103163","DOI":"10.1016\/j.critrevonc.2020.103163","article-title":"Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?","volume":"157","author":"G Colafigli","year":"2021","journal-title":"Crit Rev in Oncol Hematol"},{"issue":"5","key":"pone.0265278.ref017","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation","volume":"8","author":"S Bernardi","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0265278.ref018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"E Atallah","year":"2021","journal-title":"JAMA Oncol"},{"issue":"22","key":"pone.0265278.ref019","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"FE Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0265278.ref020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for digital PCR as an accurate molecular diagnostic tool","volume":"61","author":"JF Huggett","year":"2015","journal-title":"Clin Chem"},{"issue":"5","key":"pone.0265278.ref021","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"HG Goh","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"pone.0265278.ref022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR","volume":"16","author":"LJ Jennings","year":"2014","journal-title":"J Mol Diagn"},{"key":"pone.0265278.ref023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4939-7778-9_3","volume-title":"Digital PCR\u2014Methods and Protocols","author":"S. Tzonev","year":"2018"},{"issue":"4","key":"pone.0265278.ref024","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jmoldx.2019.03.002","article-title":"Analytical validation of a highly sensitive, multiplexed chronic myeloid leukemia monitoring system targeting BCR-ABL1 RNA","volume":"21","author":"JT Brown","year":"2019","journal-title":"J Mol Diagn"},{"key":"pone.0265278.ref025","unstructured":"Clinical Laboratory Standards Institute: EP-17A2- Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline-Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2012."},{"issue":"10","key":"pone.0265278.ref026","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"MW Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"pone.0265278.ref027","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2016.90","article-title":"Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale","volume":"30","author":"NC Cross","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"pone.0265278.ref028","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"RD Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"pone.0265278.ref029","unstructured":"Food and Drug Administration. Evaluation of automatic class III designation for quantidex qpcr bcr-abl IS kit decision summary. 2019. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN160003.pdf"},{"key":"pone.0265278.ref030","unstructured":"Clinical Laboratory Standards Institute: EP05- Evaluation of Precision of Quantitative Measurement Procedures for Clinical Laboratory Measurement Procedures; Approved Guideline-Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2014."},{"key":"pone.0265278.ref031","unstructured":"Clinical Laboratory Standards Institute: EP06- Evaluation of Linearity of Quantitative Measurement Procedures for Clinical Laboratory Measurement Procedures; Approved Guideline-First Edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2003."},{"issue":"22","key":"pone.0265278.ref032","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"HE White","year":"2010","journal-title":"Blood"},{"issue":"8476","key":"pone.0265278.ref033","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"JM Bland","year":"1986","journal-title":"Lancet"},{"key":"pone.0265278.ref034","unstructured":"Clinical Laboratory Standards Institute: EP09- Measurement Procedures Comparison and Bias Estimation Using Patient Samples for Clinical Laboratory Measurement Procedures; Approved Guideline-Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2018."},{"issue":"1","key":"pone.0265278.ref035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bjh.17521","article-title":"Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study","volume":"194","author":"S Scott","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"pone.0265278.ref036","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3892\/mmr.2014.1951","article-title":"Incidence of bcr-abl fusion transcripts in healthy individuals","volume":"9","author":"SI Ismail","year":"2014","journal-title":"Mol Med Rep"},{"issue":"9","key":"pone.0265278.ref037","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"S Bose","year":"1998","journal-title":"Blood"},{"issue":"8","key":"pone.0265278.ref038","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"C Biernaux","year":"1995","journal-title":"Blood"},{"issue":"2","key":"pone.0265278.ref039","first-page":"150","article-title":"Development of highly sensitive detection for BCR-ABL transcripts in chronic myeloid leukemia by droplet digital PCR","volume":"8","author":"C Dongngam","year":"2015","journal-title":"Thai J Genet"},{"key":"pone.0265278.ref040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jpba.2018.07.022","article-title":"Quantification of residual BHK DNA by a novel droplet digital PCR technology","volume":"159","author":"Y Wang","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"pone.0265278.ref041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmoldx.2018.08.012","article-title":"Optimized digital droplet PCR for BCR-ABL","volume":"21","author":"J Maier","year":"2019","journal-title":"J Mol Diagn"},{"issue":"1","key":"pone.0265278.ref042","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2019.08.007","article-title":"Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia","volume":"22","author":"GN Franke","year":"2020","journal-title":"J Mol Diagn"},{"issue":"1","key":"pone.0265278.ref043","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3343\/alm.2020.40.1.72","article-title":"Performance evaluation of the ddPCR BCR-ABL %IS droplet digital PCR assay","volume":"40","author":"HJ Chung","year":"2020","journal-title":"Ann Lab Med"},{"issue":"11","key":"pone.0265278.ref044","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0265278.ref045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"G Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0265278.ref046","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jmoldx.2017.01.004","article-title":"Droplet digital PCR Is a reliable tool for monitoring minimal residual disease in acute promyelocytic leukemia","volume":"19","author":"C Brunetti","year":"2017","journal-title":"J Mol Diagn"},{"issue":"7","key":"pone.0265278.ref047","first-page":"547","article-title":"Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibitor-therapy","volume":"40","author":"T Yuan","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"pone.0265278.ref048","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jmoldx.2015.07.007","article-title":"Quantification of the mutant CALR allelic burden by digital PCR: application to minimal residual disease evaluation after bone marrow transplantation","volume":"18","author":"O Mansier","year":"2016","journal-title":"J Mol Diagn"},{"issue":"11","key":"pone.0265278.ref049","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.bbmt.2016.08.014","article-title":"Multigene measurable residual disease assessment improves acute myeloid leukemia relapse risk stratification in autologous hematopoietic cell transplantation","volume":"22","author":"MP Mul\u00e9","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"pone.0265278.ref050","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"M Bill","year":"2018","journal-title":"Ann Hematol"},{"issue":"28","key":"pone.0265278.ref051","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"GR Oxnard","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0265278.ref052","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-319-42044-8_27","article-title":"Digital PCR of genomic rearrangements for monitoring circulating tumour DNA","volume":"924","author":"H Do","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"346","key":"pone.0265278.ref053","first-page":"346ra92","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"J Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"302","key":"pone.0265278.ref054","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"I Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"pone.0265278.ref055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","article-title":"Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma\u2014results of a prospective biomarker study","volume":"7","author":"A Forschner","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T17:40:19Z","timestamp":1647538819000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265278"}},"subtitle":[],"editor":[{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0265278","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]}}}